Aspirin on CTCs of Advanced Breast and Colorectal Cancer

• Status: Unknown status
• Trial end date: 2017-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether Aspirin could affect the number and subtype of circulating tumor cells of metastatic breast cancer and colorectal cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhejiang Provincial People's Hospital; Zhejiang Provincial People’s Hospital
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Adults age from 18-75 years old.

• Patients were diagnosed for metastatic breast or colorectal cancer by pathology.

• Patients who were not currently receiving intravenous chemotherapy , oral administrated with capecitabine was permitted.

• Concurrent endocrine therapy ( for at least 2 months before enrollment), bisphosphonate therapy, and/or monoclonal targeted therapy were permitted.

• PS score ≤ 3

• Anticipated survival time ≥ 3 months

• CTCs≥5 / 7.5ml blood

Exclusion Criteria:

• Allergic to aspirin or other types of non-steroid

• History of hemorrhage of digestive tract or other hemorrhagic disease

• Plan to receive surgery within the time frame of the trial

• Medication history of aspirin or other types of anti-platelets drug within one months before the trial

• Women in pregnant or lactation period

• Any psychological or objective problem may influence the compliance of the patients